Zydus Cadila gets USFDA nod for diabetes drug

NEW DELHI: Drug firm Zydus Cadila today said it has received US health regulator's approval to market generic anti-diabetes drug Pioglitazone HCL tablets in the American market.

The company has received US Food and Drug Administration's approval to market Pioglitazone HCL tablets in strengths of 15 mg, 30 mg and 45 mg, Zydus Cadila said in a filing to the BSE.

As per the research frim IMS's data, the estimated sales of Pioglitazone HCL tablets in 2012 stood at USD 2 billion in the US market.

The group now has 75 approvals and has so far filed 170 abbreviated new drug applications (ANDA), the company said.